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Background
Clinical data from the HVTN-080 study demonstrated
that intramuscular electroporation (EP) delivery of
PENNVAX®-B DNA vaccine and the plasmid adjuvant
IL-12 generated strong antigen specific cellular immune
responses in humans with nearly 90% response rate. We
have now developed minimally invasive EP delivery
technologies (MID-EP) to target dermal tissue and
demonstrate their ability to generate strong antibody
(Ab) responses in animal models with DNA antigens –
including small pox, influenza, dengue – and have
shown protection from viremia and lethality following
challenge.
Methods
We demonstrate MID-EP delivery of consensus HIV
gp140 antigens and show the generation of cross-clade
neutralizing responses in guinea pigs and rabbits. These
EP enhanced humoral responses were significantly
broader and higher than naked DNA delivery alone or
with a protein antigen. We demonstrated NAb titers
against a broad panel of 15 Tier-1 HIV viruses from
Clades A-D in the range of 20 -200 measured in the
Tzm-Bl neutralization assay. The magnitude but not the
breadth of the responses was boosted to 20-1000 range
using a MID-EP DNA prime-protein boost regimen.
Results
We further developed a surface EP device (SEP) for the
simultaneous, but spatially segregated, delivery of multi-
component HIV vaccines. The SEP device operates under
substantially lower voltage parameters than conventional
EP devices resulting in significant improvements in toler-
ability. The separation of multi-component HIV vaccines
avoids potential issues with plasmid interference at the
transcriptional or translational levels. SEP produces Ab
responses comparable to the penetrating DNAEP devices.
Conclusion
Our results suggest that MID/SEP electroporation
devices offer safe, tolerable and potent methods to
administer HIV DNA vaccinations in a prophylactic
clinical setting. Combined with the design of novel HIV
consensus based Env antigens these DNA-EP combina-
tion vaccines are suitable for further HIV vaccine pro-
duct development.
Author details
1Inovio Pharmaceuticals, Blue Bell, PA, USA. 2University of Pennsylvania
School of Medicine, Philadelphia, PA, USA.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-O9
Cite this article as: Sardesai et al.: Minimally invasive and surface
electroporation delivery of DNA vaccines for the induction of robust
humoral immune responses against HIV antigens. Retrovirology 2012
9(Suppl 2):O9.
1Inovio Pharmaceuticals, Blue Bell, PA, USA
Full list of author information is available at the end of the article
Sardesai et al. Retrovirology 2012, 9(Suppl 2):O9
http://www.retrovirology.com/content/9/S2/O9
© 2012 Sardesai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
